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Objectives. We sought to evaluate the prognostic ability of
cardiac exercise stress tests in predicting cardiac mortality and
morbidity in a low risk group of patients with established coro-
nary artery disease (CAD).
Background. Although previous studies have demonstrated the
superior value of stress nuclear cardiac scintigraphy in the
prognosis of patients with CAD, none of these studies have
focused on patients with a proven angiographic low risk profile
(i.e., single- and double-vessel CAD).
Methods. Three hundred twenty-eight patients with docu-
mented single- and double-vessel disease were treated by random
assignment to percutaneous transluminal coronary angioplasty or
medical therapy in the Angioplasty Compared to Medicine
(ACME) trial. Six months after randomization, maximal
symptom-limited exercise tests were performed with electrocardi-
ography (n 5 300) and thallium scintigraphy (n 5 270). Patients
were followed up for a minimum of 5 years thereafter.
Results. A reversible thallium perfusion deficit documented
after 6 months of either therapy was associated with an adverse
mortality outcome (18% mortality rate with a reversible thallium
perfusion defect and 8% mortality rate with no reversible thallium
perfusion deficit, p 5 0.02). Moreover, an important mortality
gradient was demonstrated in relation to the number of reperfus-
ing defects (0 5 7%, 1 to 2 5 15%, >3 5 20%, p 5 0.04). Exercise
electrocardiography did not predict this mortality outcome.
Conclusions. A reversible thallium perfusion deficit demon-
strated 6 months after medical therapy or coronary angioplasty is
a valuable prognostic marker in patients with angiographically
documented single- and double-vessel disease and is superior to
exercise electrocardiography in this regard.
(J Am Coll Cardiol 1997;30:1256–63)
©1997 by the American College of Cardiology
A number of reports have indicated that planar thallium
scintigraphic imaging can predict survival and adverse cardiac
events in patients being evaluated for chest pain (1–20). These
studies have been done in patient groups with a broad spec-
trum of risk profiles. In some of these studies, the patients did
not have coronary angiography. In other studies in which
angiography was performed, patients proved to have anywhere
from no to three-vessel or even left main coronary artery
disease (CAD) (5,9,10). This analysis was undertaken because
the Veterans Affairs–sponsored Angioplasty Compared to
Medicine (ACME) trial presented a unique opportunity to
evaluate outcomes of a highly defined group of prospectively
followed patients previously characterized by exercise testing
with thallium scintigraphy—all of whom had chronic stable
angina and a low risk profile on angiography.
All patients in ACME were required to have single- or
double-vessel disease with ejection fractions .30% at cardiac
catheterization. The initial treatment strategy proceeded along
two well defined lines to render patients angina-free with
either percutaneous transluminal coronary angioplasty
(PTCA) or optimized medical management with triple-drug
therapy. All patients were asked to return 6 months after their
random assigned treatment for follow-up exercise electrocar-
diography with thallium scintigraphy; all patients were then
followed for a minimum of 5 years thereafter. The specific
intents of this report were to evaluate whether observations
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with thallium scintigraphy performed after 6 months of these
predefined treatment strategies have prognostic import in this
selected low risk group and to compare the thallium study
results with those of exercise electrocardiography.
Methods
ACME protocol. The protocol and methods involved in
ACME have been presented elsewhere in detail (21). Pertain-
ing to this report, the methods are described briefly below.
The ACME study was designed to evaluate whether PTCA
was superior to optimized medical therapy in relieving angina
in patients with ejection fractions .30% who had single- and
double-vessel disease. A total of 328 patients were randomized
to one or the other of these therapies. More specifically, the
study entailed a clinical trial of 212 patients with subtotally
obstructive (70% to 99% stenosis) single-vessel disease (21)
and a pilot evaluation of 101 patients with double-vessel
disease (22), as well as 15 patients with totally occlusive
single-vessel disease randomized according to the identical
protocol.
The highlights of the study protocol are outlined in Figure
1. After randomization and implementation of PTCA or
medical management, patients were seen monthly. Recurrent
angina was considered an indication to either repeat PTCA in
PTCA-assigned patients or to intensify medical management
in medically assigned patients until all three classes of antian-
ginal drugs (nitrates, beta-blockers and calcium antagonists)
were used in optimal doses to provide relief of angina. At the
end of 6 months of therapy, all patients returned for a final
exercise test with thallium scintigraphy. This 6-month exercise
test was performed on the optimized medical regimen for the
patients who were assigned to medical treatment; in contrast,
because the goal of ACME was to assess the effects of
angioplasty per se as a treatment strategy, no antianginal drugs
were allowed in the preceding 24 h for those patients assigned
to PTCA therapy. The outcomes of the patients who received
this 6-month exercise study form the basis for this report.
Exercise electrocardiography and thallium scintigraphy.
All exercise electrocardiograms were performed according to
the modified Bruce protocol (initial stage: 5% elevation,
Abbreviations and Acronyms
ACME 5 Angioplasty Compared to Medicine (trial)
CAD 5 coronary artery disease
ECG 5 electrocardiogram, electrocardiographic
ETT 5 exercise tolerance test
PTCA 5 percutaneous transluminal coronary angioplasty
Figure 1. Outline of the ACME protocol. Patients
were recruited from the cardiac catheterization
laboratories at eight participating Veterans Affairs
Medical Centers. The final exercise test for PTCA-
assigned patients was done after antianginal medi-
cations were discontinued for 24 h, because the
primary goal of the study was to assess the effects of
PTCA alone compared with medical therapy on
patients’ exercise performance. EF 5 ejection frac-
tion; meds 5 medications; prn 5 as needed.
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1.7 mph) and proceeded as a symptom-limited maximal test.
Approximately 1 min before the end of exercise, 2.5 to 3.0 mCi
of intravenous thallium-201 chloride was injected; patients
were imaged in three planes (anterior, left anterior oblique
and lateral) immediately after the conclusion of exercise as
well as 3 h thereafter. Planar thallium scintigrams were qual-
itatively scored (grades 0 to 2, where 0 5 absent activity; 1 5
definitely reduced but not absent; and 2 5 normal) in nine
segments (three segments in each of three views) according to
a well validated protocol (23) at a central core laboratory. This
was done by individuals who had no knowledge of the patients’
characteristics or the nature of the treatments they received. A
response was considered positive for a reversible defect when
an exercise-induced area of hypoperfusion in any segment
improved by one or more grades in the delayed rest study.
Exercise electrocardiographic (ECG) responses were eval-
uated by computer algorithm, where a positive response was
considered 1-mm horizontal or downsloping ST segment de-
pression 0.08 s after the J point persisting for at least 15 s,
which reverted to baseline after exercise. After the 6-month
exercise study, local investigators were allowed to undertake
patient treatment according to their best judgment, which
included their own interpretation of the test results, but they
had no knowledge of the central core laboratory evaluations.
Follow-up procedures. All patients were followed for a
minimum of 60 months after randomization, initially (first 36
months) by the study assistants at each of the eight participat-
ing Veterans Affairs Medical Centers and later (all remaining
months) through a centralized telephone follow-up interview
conducted under the auspices of the West Haven Veterans
Affairs Coordinating Center.
Survival outcomes that were recorded included all-cause
mortality and cardiovascular mortality (as best as could be
determined from medical records, autopsy and death certifi-
cates and information reported by the decedents’ family). Two
of the authors (A.F.P. and E.D.F.), who had no knowledge of
the exercise study results, made these determinations indepen-
dently; any disagreements were resolved by mutual consensus.
In addition, nonfatal myocardial infarctions, subsequent hos-
pital admissions for unstable angina and subsequent cardiac
revascularization procedures were ascertained and verified
through hospital records.
Statistical analyses. Categoric variables were compared
using the chi-square test or the Fisher exact test, and contin-
uous variables were compared using the Student t test (24).
Survival analyses were based on time to failure methods,
including Kaplan-Meier estimation, log-rank testing and pro-
portional hazard regression models (25). These last models
were used to estimate relative risks. All reported p values
herein are two-sided.
Results
Stress test outcomes and survival. The mean study follow-
up time was 59.1 and 61.1 months for PTCA and medical
therapy, respectively; the median times (with 95% confidence
interval [CI]) were 64.7 (57.8 to 68.4) and 65.8 (60.1 to 67.6)
months, respectively (p 5 NS). Of the 328 randomized pa-
tients, 300 returned after 6 months for an exercise ECG; in
three tests, the ECG recordings were not adequate for inter-
pretation. Of these remaining 297 tests, 270 were performed
with thallium scintigraphy. There were a total of 43 deaths
occurring after the exercise tolerance test (ETT), 36 of which
occurred in patients whose 6-month ETT involved thallium
scintigraphy. Of the 297 exercise tests with interpretable ECG
studies, 153 were considered positive and 24 (16%) of these
153 patients died. One hundred forty-four of the exercise ECG
responses were negative, and of these, 19 patients (13%) died.
Of the 270 thallium studies, 205 were interpreted as abnormal,
having either fixed (n 5 59) or reversible (n 5 146) defects
(Table 1). There were 32 (16%) deaths in those with abnormal
tests (n 5 205) compared with four deaths in the 65 patients
(6%) with normal tests (p 5 0.06). Six (10%) of the deaths
occurred in the 59 patients with fixed defects; the majority of
the deaths (26 of 32) occurred in patients with reversible
defects, which showed the highest mortality (26 [18%] of 146)
of any test result by either modality (p 5 0.05).
A further analysis of those with reversible thallium defects
as opposed to any other result on thallium scintigraphy is
shown in Table 2. Of the thallium studies, 146 patients showed
reversible defects, 26 (18%) of whom died as compared with
124 patients who did not have reversible defects, 10 (8%) of
whom died (p 5 0.02) (Table 2, top). Kaplan-Meier survival
plots of these patient groups segregated by exercise electrocar-
diography and thallium scintigraphy are shown in Figures 2
and 3. Of particular note in Figure 2 is the continuously
widening separation of survival curves associated with negative
and positive thallium studies. At 3 years the proportion of
surviving patients who were thallium negative was 97% and
thallium positive was 94%; by 5 years these values were 93%
and 82%, respectively. When mortality was tracked by the
patient’s initial random assignment to medical therapy or
PTCA, a strong trend remained for reversible defects detected
by thallium scintigraphy to be associated with mortality (Table
2, bottom).
A mortality gradient was also demonstrable in relation to
the number of reversible defects. There was a 7% (10 of 124)
Table 1. Exercise Electrocardiographic and Scintigraphic Test
Results Versus Mortality
No. of
Pts
No. (%) of
Deaths
Total studies (ECG) 300 43 (14)
Positive 153 24 (16)
Negative 144 19 (13)
Total studies (Tl) 270 36 (13)
Normal 65 4 (6)
Abnormal 205 32 (16)
Fixed 59 6 (10)
Reversible 146 26 (18)
ECG 5 electrocardiographic; Pts 5 patients; Tl 5 thallium.
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mortality rate in patients with no reversible defects; mortality
increased to 15% (11 of 72) in those patients with one or two
reversible defects and was highest at 20% (15 of 74) in those
with three or more reversible defects (p 5 0.04).
We attempted to define the exact cause of death (as
described in the Methods section) of those 36 patients who had
thallium exercise scintigraphy at 6 months. In two instances,
information was too sketchy to define an exact cause. Of the
remaining 34 deaths, 13 were deemed to be noncardiovascular.
Of the remaining 21 cardiovascular deaths, 15 occurred in
patients with reversible defects and 6 in patients without
reversible defects.
Nonfatal cardiac events. Table 3 lists the number of non-
fatal myocardial infarctions, hospital admissions for unstable
angina and late (after the 6-month ETT) revascularizations in
patients with positive and negative exercise ECG and thallium
scintigraphic studies. There was no significant difference in the
distribution of these nonfatal events between patients with
positive studies and those with negative studies, irrespective of
the specific type of stress test. This also remained true whether
the initial patient assignment was to PTCA or medical therapy.
Table 2. Mortality in ACME Follow-Up Study
Tl1 Tl2
p Value
(chi-square) ECG1 ECG2
p Value
(chi-square)
Overall
No. of pts 146 124 153 144
Died [no. (%)] 26 (18) 10 (8) 0.02 24 (16) 19 (13) 0.54
PTCA
No. of pts 66 71 81 70
Died [no. (%)] 13 (20) 5 (7) 0.03 13 (16) 8 (11) 0.41
Medical
No. of pts 80 53 72 74
Died [no. (%)] 13 (16) 5 (9) 0.26 11 (15) 11 (15) 0.94
ECG1 (ECG2) 5 presence (absence) of exercise-induced 1-mm horizontal or downsloping ST segment depression
on the electrocardiogram; PTCA 5 percutaneous transluminal coronary angioplasty; pts 5 patients; Tl1 (Tl2) 5
presence (absence) of reversible thallium defects.
Figure 2. Kaplan-Meier survival curves for patients having exercise
thallium scintigraphic studies 6 months after randomization. A test was
considered positive if there was an exercise-induced defect that
improved in the subsequent rest study.
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Comparability of patients with and without reversible
perfusion defects. The baseline characteristics of the patients
with and without reversible defects are listed in Table 4. The
clinical risk profile of these patients is identical in terms of age,
underlying disease, current smoking status, lipid profile and
more. By 6 months, cholesterol and low density lipoprotein
cholesterol had decreased in all patients, but were not different
between those with and those without reversible defects (Table
4). However, there was a greater proportion of revascularized
patients with no reperfusion defects; this latter group had a
greater duration on treadmill exercise than the group with
reversible defects. In contrast, a greater proportion of medi-
cally assigned patients had reversible defects (Table 4).
Predictors of survival. Lifetable regression analyses evalu-
ating risk factors pertaining to survival in this patient group are
shown in Table 5. Univariate regression analyses showed that
age, ejection fraction, diabetes, reversible thallium defect and
current smoking had the strongest individual relations to
subsequent survival. When these five variables were combined
in a multivariate model, the highest relative risks were ob-
served in patients with diabetes, a reversible thallium defect
and current smoking.
Discussion
Findings in relation to characteristics of the ACME study
group. The findings reported herein support and extend mul-
tiple previous observations that stress thallium scintigraphy has
important prognostic value in patients with established CAD.
The patients in ACME were randomized to two distinct initial
treatment strategies. All the patients had a low risk profile in
comparison to the previously evaluated group of patients with
CAD. None had an acute coronary syndrome; all completed a
maximal treadmill exercise test while off of all medications in
order to enter the study. None had left main or three-vessel
disease and none had a previous revascularization procedure
at randomization. Our thallium studies were performed after
all of the patients had received standardized treatment along
two acceptable lines (i.e., either maximal medical therapy to
relieve angina in the medical cohort or PTCA, as well as repeat
PTCA if needed), with the goal of achieving complete freedom
from angina in the PTCA cohort. Exercise thallium scintigra-
phy proved superior to exercise electrocardiography in predict-
ing subsequent mortality—the majority of which was cardio-
vascular. When evaluated concomitantly with clinical risk
factors, only diabetes and current smoking emerged as predic-
tors of comparable magnitude.
Previous studies of exercise thallium scintigraphy and
patient outcomes. The published reports focusing primarily on
planar thallium imaging in patients with known or suspected
CAD were reviewed by Brown in 1991 (19) and more recently
by Heller and Brown in 1994 (26) and an American Heart
Figure 3. Kaplan-Meier survival curves for patients undergoing ETT
with ECG monitoring. A positive test was one in which there was
$1.0 mm of horizontal or downsloping exercise-induced ST segment
depression 0.08 s after the J point persisting for at least 15 s.
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Association/American College of Cardiology Task Force (27).
Multiple independent studies involving more than 6,000 pa-
tients have shown that a perfusion deficit, in particular, a
reversible deficit on planar exercise thallium scintigraphy, is
the dominant predictor of subsequent cardiac events, including
cardiac death, nonfatal myocardial infarction and late coronary
revascularization. However, of the more than 6,000 patients
represented in these reviews, ,25% had had a previous cardiac
catheterization. Only two of these studies involved follow-up
periods of more than 5 years (9,11).
Kaul et al. (5) reported on 299 ambulatory patients with
chest pain followed for a mean duration of 4.6 years, studied at
the University of Virginia. At cardiac catheterization, 93 of
these patients had no identifiable CAD, 77 had three-vessel
disease and 5 left main disease. The remaining 124 had single-
and double-vessel disease. The best predictors of subsequent
outcome were the number of diseased vessels and the number
of reversible defects on exercise thallium scintigraphy. Another
large study involving cardiac catheterization data of 204 pa-
tients studied for a mean of 5.3 years was also performed by
Kaul et al. (9) at the Massachusetts General Hospital. Again,
the patient group included individuals with triple-vessel dis-
ease. Exercise thallium scintigraphy had a slightly better pre-
dictive ability than cardiac catheterization. Of the 20 deaths
reported, 15 were in patients with reversible defects.
In 1993, Brown and Rowen (28) reported on 75 patients
with negative thallium studies, 60 of whom (80%) had single-
and double-vessel disease. At a mean 2-year follow-up, there
were no deaths and only one nonfatal myocardial infarction in
this cohort. Our survival analysis of 124 patients with no
redistributing defects (Fig. 2) shows similarly excellent survival
at 2 years, by which time only one of these patients had died.
Table 3. Late Coronary and Revascularization Events in ACME Study*
Tl1 Tl2 p
Value
ECG1 ECG2 p
Value(n 5 146) (n 5 124) (n 5 153) (n 5 144)
MI 11 (7) 6 (5) 0.36 8 (5) 12 (8) 0.29
USA 35 (24) 32 (26) 0.73 39 (26) 30 (21) 0.34
PTCA 41 (28) 26 (21) 0.18 39 (26) 31 (21) 0.42
CABG 26 (18) 23 (19) 0.88 31 (20) 20 (14) 0.15
*After 6-month exercise treadmill test. Data presented are number (%) of patients. CABG 5 coronary artery bypass
graft surgery; MI 5 myocardial infarction; USA 5 unstable angina; other abbreviations as in Table 2.
Table 4. Clinical and Angiographic Characteristics of Study Patients
at Baseline and at Six-Month Exercise Study
Reversible
Defect
No
Reversible
Defect p
Value(n 5 146) (n 5 124)
Baseline
Age (yr) 60.9 6 8.4 59.8 6 7.7 0.29
Hypertension 81 (55%) 73 (59%) 0.57
Diabetes 25 (17%) 25 (20%) 0.52
Current smoker 46 (32%) 37 (30%) 0.77
Max % stenosis 86 6 10.1 85 6 10.2 0.39
SBP (mm Hg) 136 6 18 135 6 17.1 0.79
DBP (mm Hg) 80 6 11 81 6 9.6 0.22
ETT duration (min) 8.1 6 2.8 8.6 6 3.0 0.15
TC (mg/dl) 236 6 45 228 6 48 0.15
LDL-C (mg/dl) 159 6 38.9 152 6 41.8 0.16
Prior MI 48 (33%) 50 (40%) 0.20
LVEF (%) 68.1 6 11 67 6 11 0.40
1 VD 97 91 0.66
2 VD 49 33 0.08
6 mo ETT
TC (mg/dl) 216 6 35 221 6 42 0.26
LDL-C (mg/dl) 139 6 36 145 6 38 0.21
Assigned treatment
PTCA 66 (45%) 71 (57%) 0.67
Medical 80 (55%) 53 (43%) 0.02
Revasc (before 6-mo ETT) 74 (51%) 78 (63%) 0.04
ETT duration (min) 9.0 6 2.9 10.5 6 3.3 ,0.01
Data presented are mean value 6 SD or number (%) of patients. DBP 5
diastolic blood pressure; ETT 5 exercise treadmill test; LDL-C 5 low density
lipoprotein cholesterol; LVEF 5 left ventricular ejection fraction; Max 5
maximal; Revasc 5 revascularization; SBP 5 systolic blood pressure; TC 5 total
cholesterol; VD 5 vessel disease; other abbreviations as in Table 3.
Table 5. Risk Ratios for Survival in Relation to
Patient Characteristics
Variable RR (95% CI)
p Value
(Wald chi-square)
Univariate model
Age 1.04 (0.99–1.09) 0.09
LVEF 0.97 (0.94–0.99) 0.04
2 VD 1.26 (0.65–2.41) 0.49
Body mass index 1.01 (0.93–1.10) 0.77
Diabetes 2.95 (1.51–5.77) 0.002
LDL-C (baseline) 0.99 (0.98–1.00) 0.89
Hypertension 1.06 (0.55–2.06) 0.87
ST depression 1.22 (0.67–2.24) 0.51
Reversible defect 1.97 (0.97–4.01 0.03
Treatment assigned 1.03 (0.57–1.87 0.92
Revasc (6 mo) 0.74 (0.41–1.34) 0.32
Current smoker (baseline) 1.53 (0.78–3.00) 0.21
Multivariate model*
Diabetes 2.83 (1.36–5.88) 0.01
Reversible defect 2.23 (1.03–4.82) 0.04
Current smoker 2.19 (1.01–4.75) 0.05
LVEF 0.98 (0.95–1.00) 0.08
Age 1.04 (0.99–1.10) 0.13
*Includes the five variables with lowest p values in univariate model. CI 5
confidence interval; RR 5 risk ratio; other abbreviations as in Table 4.
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Previously, Iskandrian et al. (29) reported on a series of 781
patients with suspected or known CAD and found that the
total number of perfusion defects was the single most powerful
predictor of adverse events (cardiac death and nonfatal myo-
cardial infarction). Our finding of a significant increase in
mortality in relation to the total number of reversible defects is
consistent with this finding.
No previous study has exclusively focused on patients with
proven CAD who had a low risk profile clinically and angio-
graphically and then were prospectively followed. Our findings
thus extend previous observations supporting the value of
thallium scintigraphy as a predictor of subsequent mortality in
such low risk patients.
Study limitations. Our conclusions are applicable to men
.60 years of age and who have the clinical and angiographic
risk profile defined earlier. The ACME protocol required use
of antianginal medication for medically assigned patients on
the 6-month exercise study; such medications were proscribed
for the 24 h preceding this test in the PTCA-assigned patients.
Nevertheless, treatment assignment did not confer a survival
advantage or disadvantage when evaluated by regression anal-
ysis (Table 5). Single-photon emission computed tomographic
thallium scintigraphy has now replaced planar thallium imag-
ing in most centers. This modality has comparable, if not
superior, predictive power to that of planar thallium imaging
for determining prognosis in patients with CAD (10,30–36),
particularly when a reversible defect is elicited (20,30,32,35).
Finally, our study reports all-cause mortality. A number of
patients in the 60-year-old age group, when followed for 5 or
more years, will die of cancer. Nevertheless, the majority of
deaths (21 of 34) in this group were directly attributable to
cardiovascular disease; of these 21 deaths, there were over two
times (15 vs. 6) more cardiovascular deaths in patients with
reversible defects.
Conclusions. Exercise thallium scintigraphy is a valuable
predictor of subsequent mortality in men with a low angio-
graphic risk profile who present with stable coronary syn-
dromes. In the ACME study, the prognostic power of exercise
thallium scintigraphy was superior to that of exercise ECG
findings and comparable to diabetes and current smoking as an
adverse marker for subsequent survival.
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